HRP20110860T1 - Supstituirani derivati heteroarilpiperidina kao modulatori receptora melanokortina-4 - Google Patents
Supstituirani derivati heteroarilpiperidina kao modulatori receptora melanokortina-4 Download PDFInfo
- Publication number
- HRP20110860T1 HRP20110860T1 HR20110860T HRP20110860T HRP20110860T1 HR P20110860 T1 HRP20110860 T1 HR P20110860T1 HR 20110860 T HR20110860 T HR 20110860T HR P20110860 T HRP20110860 T HR P20110860T HR P20110860 T1 HRP20110860 T1 HR P20110860T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- halogen
- optionally substituted
- alkylene
- substituents selected
- Prior art date
Links
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title abstract 4
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 238000011282 treatment Methods 0.000 claims abstract 6
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 3
- 206010006895 Cachexia Diseases 0.000 claims abstract 3
- 208000008589 Obesity Diseases 0.000 claims abstract 3
- 208000022531 anorexia Diseases 0.000 claims abstract 3
- 230000036506 anxiety Effects 0.000 claims abstract 3
- 206010061428 decreased appetite Diseases 0.000 claims abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 3
- 235000020824 obesity Nutrition 0.000 claims abstract 3
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract 2
- 201000000585 muscular atrophy Diseases 0.000 claims abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 102000057094 human MC4R Human genes 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07014219A EP2019100A1 (en) | 2007-07-19 | 2007-07-19 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| PCT/EP2008/005913 WO2009010299A1 (en) | 2007-07-19 | 2008-07-18 | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110860T1 true HRP20110860T1 (hr) | 2011-12-31 |
Family
ID=38728783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110860T HRP20110860T1 (hr) | 2007-07-19 | 2011-11-18 | Supstituirani derivati heteroarilpiperidina kao modulatori receptora melanokortina-4 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20100249093A1 (es) |
| EP (2) | EP2019100A1 (es) |
| JP (1) | JP2010533666A (es) |
| KR (1) | KR20100033541A (es) |
| CN (1) | CN101801950A (es) |
| AT (1) | ATE530541T1 (es) |
| AU (1) | AU2008277916B2 (es) |
| BR (1) | BRPI0814382A2 (es) |
| CA (1) | CA2694480C (es) |
| DK (1) | DK2176250T3 (es) |
| ES (1) | ES2371626T3 (es) |
| HR (1) | HRP20110860T1 (es) |
| IL (1) | IL202797A0 (es) |
| NZ (1) | NZ582153A (es) |
| PL (1) | PL2176250T3 (es) |
| PT (1) | PT2176250E (es) |
| RU (1) | RU2452734C2 (es) |
| SI (1) | SI2176250T1 (es) |
| WO (1) | WO2009010299A1 (es) |
| ZA (1) | ZA201000153B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105753706A (zh) | 2008-04-16 | 2016-07-13 | 安格斯化学公司 | 硝化烃、衍生物和它们的制造方法 |
| CN102007093B (zh) * | 2008-04-16 | 2014-07-02 | 安格斯化学公司 | 用于制备硝基丙烷的方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HUE041509T2 (hu) | 2011-12-22 | 2019-05-28 | Janssen Biopharma Inc | Szubsztituált nukleozidok, nukleotidok és ezek analógjai |
| HUE056948T2 (hu) | 2011-12-29 | 2022-04-28 | Rhythm Pharmaceuticals Inc | Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
| WO2014081619A1 (en) * | 2012-11-20 | 2014-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| CA2894542C (en) | 2012-12-21 | 2023-10-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| MA43040A (fr) | 2015-09-30 | 2018-08-08 | Univ Berlin Charite | Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4 |
| AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CN109879766A (zh) * | 2019-03-02 | 2019-06-14 | 台州保灵药业有限公司 | 一种3-(nn-二甲基）氨基丁醇的合成方法 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60205465T2 (de) * | 2001-01-23 | 2006-04-20 | Eli Lilly And Co., Indianapolis | Piperazinderivate als agonisten des melanocortin-rezeptors |
| US6977264B2 (en) * | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US20040010010A1 (en) * | 2002-04-30 | 2004-01-15 | Ebetino Frank Hallock | Melanocortin receptor ligands |
| AU2003268493A1 (en) * | 2002-09-11 | 2004-04-30 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| KR20050045927A (ko) * | 2003-11-12 | 2005-05-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| US7649002B2 (en) * | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| CA2642922C (en) * | 2006-02-23 | 2011-08-02 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| EP1842846A1 (en) * | 2006-04-07 | 2007-10-10 | Santhera Pharmaceuticals (Schweiz) AG | Phenylpiperidine derivatives as melanocortin-4 receptor modulators |
-
2007
- 2007-07-19 EP EP07014219A patent/EP2019100A1/en not_active Withdrawn
-
2008
- 2008-07-18 WO PCT/EP2008/005913 patent/WO2009010299A1/en active Application Filing
- 2008-07-18 JP JP2010516425A patent/JP2010533666A/ja not_active Ceased
- 2008-07-18 CA CA2694480A patent/CA2694480C/en not_active Expired - Fee Related
- 2008-07-18 PT PT08784892T patent/PT2176250E/pt unknown
- 2008-07-18 SI SI200830492T patent/SI2176250T1/sl unknown
- 2008-07-18 AU AU2008277916A patent/AU2008277916B2/en not_active Ceased
- 2008-07-18 PL PL08784892T patent/PL2176250T3/pl unknown
- 2008-07-18 DK DK08784892.5T patent/DK2176250T3/da active
- 2008-07-18 NZ NZ582153A patent/NZ582153A/en not_active IP Right Cessation
- 2008-07-18 CN CN200880025309A patent/CN101801950A/zh active Pending
- 2008-07-18 ES ES08784892T patent/ES2371626T3/es active Active
- 2008-07-18 AT AT08784892T patent/ATE530541T1/de active
- 2008-07-18 EP EP08784892A patent/EP2176250B1/en not_active Not-in-force
- 2008-07-18 RU RU2009147775/04A patent/RU2452734C2/ru not_active IP Right Cessation
- 2008-07-18 US US12/665,771 patent/US20100249093A1/en not_active Abandoned
- 2008-07-18 KR KR1020107003537A patent/KR20100033541A/ko active IP Right Grant
- 2008-07-18 BR BRPI0814382-0A2A patent/BRPI0814382A2/pt not_active IP Right Cessation
-
2009
- 2009-12-17 IL IL202797A patent/IL202797A0/en unknown
-
2010
- 2010-01-08 ZA ZA201000153A patent/ZA201000153B/xx unknown
-
2011
- 2011-11-18 HR HR20110860T patent/HRP20110860T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2694480C (en) | 2012-05-15 |
| WO2009010299A1 (en) | 2009-01-22 |
| EP2176250A1 (en) | 2010-04-21 |
| CN101801950A (zh) | 2010-08-11 |
| PL2176250T3 (pl) | 2012-03-30 |
| ES2371626T3 (es) | 2012-01-05 |
| ZA201000153B (en) | 2010-09-29 |
| WO2009010299A8 (en) | 2009-04-02 |
| SI2176250T1 (sl) | 2012-01-31 |
| BRPI0814382A2 (pt) | 2015-01-27 |
| PT2176250E (pt) | 2011-12-15 |
| AU2008277916A1 (en) | 2009-01-22 |
| NZ582153A (en) | 2011-09-30 |
| DK2176250T3 (da) | 2012-02-13 |
| US20100249093A1 (en) | 2010-09-30 |
| KR20100033541A (ko) | 2010-03-30 |
| IL202797A0 (en) | 2010-06-30 |
| ATE530541T1 (de) | 2011-11-15 |
| EP2019100A1 (en) | 2009-01-28 |
| RU2009147775A (ru) | 2011-08-27 |
| AU2008277916B2 (en) | 2012-02-02 |
| RU2452734C2 (ru) | 2012-06-10 |
| EP2176250B1 (en) | 2011-10-26 |
| CA2694480A1 (en) | 2009-01-22 |
| JP2010533666A (ja) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110860T1 (hr) | Supstituirani derivati heteroarilpiperidina kao modulatori receptora melanokortina-4 | |
| HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| HRP20170317T1 (hr) | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza | |
| CA2540541A1 (en) | Alkoxy substituted imidazoquinolines | |
| AR067845A1 (es) | Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica | |
| GT200500368A (es) | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios | |
| CA2628131A1 (en) | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| DE60336014D1 (de) | Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen | |
| RS51163B (sr) | Dihidrotienopirimidin za lečenje zapaljenskih bolesti | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
| ATE484502T1 (de) | Neue verbindungen | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| GB0517191D0 (en) | Compounds | |
| BR0112856A (pt) | Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos | |
| RU2007146512A (ru) | N, n-замещенные 3-аминопирролидиновые соединения, полезные в качестве ингибиторов повторного поглощения моноаминов | |
| GB0507680D0 (en) | Compounds |